The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements
Open accessAbstract
Nearly 30% of currently approved recombinant therapeutic proteins are produced in Escherichia coli. Due to its well-characterized genetics, rapid growth and high-yield production, E. coli has been a preferred choice and a workhorse for expression of non-glycosylated proteins in the biotech industry. There is a wealth of knowledge and comprehensive tools for E. coli systems, such as expression vectors, production strains, protein folding and fermentation technologies, that are well tailored for industrial applications. Advancement of the systems continues to meet the current industry needs, which are best illustrated by the recent drug approval of E. coli produced antibody fragments and Fc-fusion proteins by the FDA. Even more, recent progress in expression of complex proteins such as full-length aglycosylated antibodies, novel strain engineering, bacterial N-glycosylation and cell-free systems further suggests that complex proteins and humanized glycoproteins may be produced in E. coli in large quantities. This review summarizes the current technology used for commercial production of recombinant therapeutics in E. coli and recent advances that can potentially expand the use of this system toward more sophisticated protein therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED ARTICLE: Strategies for efficient production of heterologous proteins in Escherichia coli
Jana, S., & Deb, J. K. (2005) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-004-1814-0 · Cited by 349
RetractedRetraction Note: Strategies for efficient production of heterologous proteins in Escherichia coli
Jana, S., & Deb, J. K. (2014) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-014-5822-4 · Cited by 212
RetractedUse of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes
Studier, F. W., & Moffatt, B. A. (1986) · Journal of Molecular Biology · doi:10.1016/0022-2836(86)90385-2 · Cited by 6,320
Automated design of synthetic ribosome binding sites to control protein expression
Salis, H. M., Mirsky, E. A., & Voigt, C. A. (2009) · Nature Biotechnology · doi:10.1038/nbt.1568 · Cited by 1,844
Recombinant protein expression in Escherichia coli
Baneyx, F. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00003-8 · Cited by 1,481
Codon bias and heterologous protein expression
Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330
Strategies for achieving high-level expression of genes in Escherichia coli
Makrides, S. C. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.3.512-538.1996 · Cited by 1,276
Terpe, K. (2006) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-006-0465-8 · Cited by 1,036
High cell-density culture of Escherichia coli
Lee, S. Y. (1996) · Trends in Biotechnology · doi:10.1016/0167-7799(96)80930-9 · Cited by 880
N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into E. coli
Wacker, M., Linton, D., Hitchen, P. G., Nita-Lazar, M., Haslam, S. M., North, S. J., Panico, M., Morris, H. R., Dell, A., Wren, B. W., et al. (2002) · Science · doi:10.1126/science.298.5599.1790 · Cited by 777
Cited by
The unexhausted potential of E. coli
Blount, Z. D. (2015) · eLife · doi:10.7554/elife.05826 · Cited by 424
Cell factories for insulin production
Baeshen, N. A., Baeshen, M. N., Sheikh, A., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., & Redwan, E. M. (2014) · Microbial Cell Factories · doi:10.1186/s12934-014-0141-0 · Cited by 359
Detoxifying Escherichia coli for endotoxin-free production of recombinant proteins
Mamat, U., Wilke, K., Bramhill, D., Schromm, A. B., Lindner, B., Kohl, T. A., Corchero, J. L., Villaverde, A., Schaffer, L., Head, S. R., et al. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0241-5 · Cited by 274
Microbials for the production of monoclonal antibodies and antibody fragments
Spadiut, O., Capone, S., Krainer, F., Glieder, A., & Herwig, C. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.10.002 · Cited by 258
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134
“The bacterial cytoplasm provides ample space for protein accumulation and is generally well-suited for the expression of most soluble recombinant proteins [107].”
Background
Metadata
- Authors
- Huang, C.-J., Lin, H., & Yang, X.
- Venue
- Journal of Industrial Microbiology and Biotechnology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-01
- Volume
- 39
- Issue
- 3
- Pages
- 383-399
- ISSN
- 1367-5435 (ISSN-L)
- 1476-5535
- OpenAlex
- W2470014202
- Cited by
- 424
- References
- 108
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. https://app.cochat.ai/papers/10.1007/s10295-011-1082-9
- The paper
- Huang, C.-J., Lin, H., & Yang, X. (2012). Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. Journal of Industrial Microbiology and Biotechnology. https://doi.org/10.1007/s10295-011-1082-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.